Startups
Akili Interactive
Boston, Massachusetts, United States · San Francisco, California, United States
Akili Interactive is the cognitive digital-medicine business founded in2011 through PureTech Health, with scientific and game-design founders including Eddie Martucci, Adam Gazzaley, Matthew Omernick and Adam Piper. Its Boston/San Francisco team developed neuroscience-based video-game treatments, including EndeavorRx and EndeavorOTC for attention difficulties associated with ADHD. Proprietary adaptive algorithms adjust sensory and motor challenges to engage attentional-control systems. It is relevant to neuroscience, adaptive software and digital therapeutics; the public sources do not establish a generative-AI model business. Regulatory and clinical efficacy claims are product- and population-specific, not a general treatment claim for every condition in its investigational pipeline. Akili Interactive Labs Inc became the operating subsidiary of public Akili Inc following its August19,2022 combination with Social Capital Suvretta Holdings Corp I. Virtual Therapeutics Corporation acquired Akili Inc on July2,2024 and took it private; the current parent website vthera.com continues to publish EndeavorRx/OTC. The0.434-dollar-per-share takeover price was acquisition consideration, not new financing. All seven public directors resigned at closing; Daniel J Elenbaas became sole director/president and Matt McIntire treasurer/secretary. Surviving executive bios and2017–2023 appointments are explicitly dated, with current post-acquisition operating status unverified; board resignations are recorded. No current private-company employee roster is publicly available. Primary venture announcements document30.5MSeriesB inJanuary2016,11.9MBextension inJuly2016,55MC inMay2018,13MCextension inAugust2018 and110MD equity inMay2021. The2021 headline160M includes an up-to50Mcreditfacility, not160Mequity. SEC disclosures separately establish actualSVBdraws5M inMay2021 and10M inJune2022, and a5MShionogi bond inMarch2019; facility ceilings and undrawn tranches are excluded from cash. The2022SPAC transaction generated162MactualPIPE and2.283Mtrust cash; the412Mforecast and1Bvaluation are not new actual proceeds. Shionogi licensing upfronts, future contingent milestones, royalty revenue and clinical partnerships are distinct from financing. EarlierSeriesAcapital remains unspecified where date/size is not verified.
Founded 2011
Team
 Adam GazzaleyCo-Founder and Chief Scientific Advisor (last published bio; post-acquisition operating status unverified) |
Adam PiperCo-Founder (historical founding affiliation) |
Anil S. JinaSenior Vice President and Head of Medical Affairs (November2018; current status unverified) |
 Bennett ShapiroClinical Advisory Committee Member (November2018; current status unverified) |
 Bharatt ChowriraFormer Board Director (November2017–September2019 and June2021–October2022) |
Carmen BozicClinical Advisory Committee Member (November2018; current status unverified) |
 Caty ReidVice President, Marketing and Communications (last published bio; post-acquisition operating status unverified) |
 Daniel J ElenbaasSole Director and President (appointed July2,2024; last confirmed governance) |
Eddie MartucciCo-Founder |
Glenn EntisExecutive Advisor (2017; current status unverified) |
 Jacqueline StuderChief Legal Officer and General Counsel (last published bio; post-acquisition operating status unverified) |
 Jon DavidChief Product Officer (last published bio; post-acquisition operating status unverified) |
 Ken EhlertBoard Director (October2022; later service unverified) |
Matt McIntireTreasurer and Secretary (appointed July2,2024; last confirmed governance) |
 Matthew Franklin (Akili)Chief Executive Officer (last published bio; post-acquisition operating status unverified) |
Matthew OmernickCo-Founder (historical founding affiliation) |
 Meghan RiveraFormer Chief Marketing Officer and Head of Commercial (appointed October2020; left by March2022) |
Noah FalsteinExecutive Advisor (2017; current status unverified) |
Philip NinanClinical Advisory Committee Member (November2018; current status unverified) |
Robert J PerezExecutive Chairman (2017 appointment; later service unverified) |
Santosh ShanbhagFormer Chief Financial Officer (appointed April2019; left by January2024) |
 Scott KollinsChief Medical Officer (last published bio; post-acquisition operating status unverified) · Clinical Advisory Committee Member (November2018; current status unverified) |